Finance

Beta
Lists
17Q1:FRA
Pharmaron Beijing Ord Shs H
€1.84
+6.36%
(+0.11) 1D
Jun 5, 9:59:11 AM GMT+2  ·   EUR
All symbols
SymbolPriceChange% Change
Generating top insights for 17Q1...
Open
€1.77
High
€1.84
Low
€1.77
Mkt. cap
45.59B
Avg. vol.
14.00
Volume
6.00
52-wk high
€3.24
52-wk low
€1.65
No. of employees
25K
Open
€1.77
High
€1.84
Low
€1.77
Mkt. cap
45.59B
Avg. vol.
14.00
Volume
6.00
52-wk high
€3.24
52-wk low
€1.65
No. of employees
25K
News stories
From sources across the web
About Pharmaron Beijing Ord Shs H
CEOBoliang Lou
Employees25.1K
FoundedJul 1, 2004
Headquarters-
SectorHealth care
Websitepharmaron.cn
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
3.34B
3.64B
4.01B
3.58B
Cost of goods sold
2.20B
2.38B
2.57B
2.42B
Cost of revenue
2.20B
2.38B
2.57B
2.42B
Research and development expenses
128.25M
141.14M
184.42M
139.77M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
482.58M
540.84M
553.55M
520.12M
Operating expense
679.38M
744.80M
809.09M
701.15M
Total operating expenses
2.88B
3.13B
3.38B
3.12B
Operating income
465.33M
519.36M
629.52M
461.69M
Other non operating income
5.74M
-37.81M
36.17M
-48.69M
EBT including unusual items
449.17M
516.18M
583.78M
412.76M
EBT excluding unusual items
399.54M
478.50M
626.67M
396.21M
Income tax expense
76.19M
102.94M
94.46M
102.35M
Effective tax rate
16.96%
19.94%
16.18%
24.80%
Other operating expenses
42.80M
56.34M
34.47M
29.75M
Net income
395.82M
439.52M
522.99M
335.36M
Net profit margin
11.84%
12.06%
13.04%
9.37%
Earnings per share
0.20
0.27
0.33
-
Interest and investment income
10.74M
12.46M
9.47M
34.76M
Interest expense
-50.29M
-47.49M
-51.15M
-51.56M
Net interest expenses
-39.56M
-35.03M
-41.68M
-16.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
704.71M
735.19M
881.17M
713.34M
Gain or loss from assets sale
3.36M
-3.36M
4.69M
-
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer